Nanotherapeutics’ bone void filler receives expanded FDA 510(k) marketing clearance

Nanotherapeutics received expanded 510(k) marketing clearance from the U.S. Food and Drug Administration for use of NanoFUSE DBM in spinal fusion.

Advertisement
By: Staff

NanoFUSE DBM is the company’s proprietary bone void filler product. Specifically, it has been cleared for use with autograft as a bone graft extender in the posterolateral spine. It is the first off-the-shelf DBM product containing bioactive glass available for use in an orthopedic clinical setting.

More articles on devices:

Amedica brings on with PCG Advisory as agency of record
OrthoWorx commits $475k on workforce development — 6 initiatives
Mesoblast gets patent for mesenchymal precursor cell technology — 7 thing to know

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Why payment delivery is becoming a competitive advantage for payers

Recommended Whitepaper

Advertisement

Next Up in Spinal Tech

  • 2 spine medtech lawsuit updates

    Since March 25, there have been two key developments in lawsuits involving spine medtech companies. 1. The U.S. Court of…

    By: Carly Behm

  • Top-paid spine medtech CFOs

    The highest-paid CFOs at spine and orthopedic medtech companies saw total compensation reaching in the mid-single digits and beyond. Here…

    By: Carly Behm
Advertisement

Comments are closed.